Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Shree Ganesh Biotech (India)'s Revenue for the
three
months ended in Jun. 2026 was ₹14.30 Mil. Shree Ganesh Biotech (India)'s average Accounts Receivable for the
three
months ended in Jun. 2026 was ₹0.00 Mil.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Shree Ganesh Biotech (India) Receivables Turnover Related Terms
Shree Ganesh Biotech (India) Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:539470 vs CTVA, CF, MOS: Receivables Turnover Comparison
For the Agricultural Inputs subindustry, Shree Ganesh Biotech (India)'s Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shree Ganesh Biotech (India) Receivables Turnover vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, Shree Ganesh Biotech (India)'s Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Shree Ganesh Biotech (India)'s Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shree Ganesh Biotech (India) (BOM:539470) has a Receivables Turnover of 0.00 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Shree Ganesh Biotech (India) and its competitors. According to the industry distribution chart, Shree Ganesh Biotech (India) ranks #999999 out of 248 companies in the Agriculture industry.
Is Shree Ganesh Biotech (India)'s Receivables Turnover too high?
Shree Ganesh Biotech (India)'s current Receivables Turnover is 0.00. Based on the distribution chart, Shree Ganesh Biotech (India) ranks #999999 out of 248 companies in the Agriculture industry, which is in the bottom quartile relative to peers. Overall, Shree Ganesh Biotech (India) has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shree Ganesh Biotech (India)'s Receivables Turnover compare to CTVA and CF?
According to the Agriculture industry distribution chart, Shree Ganesh Biotech (India) ranks #999999 out of 248 companies for Receivables Turnover. This places Shree Ganesh Biotech (India) in the lower half of its industry. The industry median Receivables Turnover is 5.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for an Agriculture company?
The median Receivables Turnover among Agriculture companies is 5.60, based on 248 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Shree Ganesh Biotech (India) and its competitors. For the Agriculture industry, the median Receivables Turnover is 5.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shree Ganesh Biotech (India)'s current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shree Ganesh Biotech (India) stock overvalued right now?
Based on GuruFocus' analysis, Shree Ganesh Biotech (India) (BOM:539470) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹0.25, compared to a current price of ₹0.49 — trading 96% above its estimated fair value. The current Receivables Turnover is 0.00. Shree Ganesh Biotech (India)'s overall GF Score™ is 45/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Shree Ganesh Biotech (India) (BOM:539470), the current Receivables Turnover is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shree Ganesh Biotech (India) (BOM:539470) Overvalued in 2026?
Based on GuruFocus' analysis, Shree Ganesh Biotech (India) stock appears to be overvalued.
The current stock price of ₹0.49 is trading 96% above its estimated GF Value™ of ₹0.25.
GuruFocus considers Shree Ganesh Biotech (India) to be Significantly Overvalued.
Key valuation signals for BOM:539470:
Receivables Turnover: 0.00
GF Value™: ₹0.25 vs. price of ₹0.49 (96% above fair value)
No single metric tells the full story. See the BOM:539470 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shree Ganesh Biotech (India) Ltd is an India-based company mainly engaged in the business of production, processing and marketing of high-quality hybrid seeds for different crops like corn, sunflower, cotton, paddy, grain sorghum, etc.
45GF Score
Get the complete analysis for BOM:539470
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539470 has been successfully added to your 
